SRP 299

Identification

Name
SRP 299
Accession Number
DB05440
Type
Small Molecule
Groups
Investigational
Description

SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity. A specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in asthma, atopic dermatitis, and pediatric atopic dermatitis indications.

Pharmacodynamics

Induces peripheral immune activation through the activity of regulatory T-cells

Mechanism of action

Induces activity of regulatory t-cells that surpress Th2 activity. CD11c+ cells act as the primary target for M. vaccae.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of SRP 299 can be decreased when used in combination with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of SRP 299 can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of SRP 299 can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Acetyl sulfisoxazole.
ActeosideThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of SRP 299 can be decreased when used in combination with Aldesleukin.
Food Interactions
Not Available

References

General References
  1. Arkwright PD, Fujisawa C, Tanaka A, Matsuda H: Mycobacterium vaccae reduces scratching behavior but not the rash in NC mice with eczema: a randomized, blinded, placebo-controlled trial. J Invest Dermatol. 2005 Jan;124(1):140-3. [PubMed:15654967]
  2. Breivik T, Rook GA: Oral treatment with SRP299 (killed Mycobacterium vaccae) inhibits experimental periodontal disease in Wistar rats. J Clin Periodontol. 2003 Nov;30(11):931-6. [PubMed:14761113]
External Links
PubChem Substance
347910140

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:25 / Updated on October 01, 2018 14:01